Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view

Clin Transl Oncol. 2021 Sep;23(9):1961-1962. doi: 10.1007/s12094-021-02584-y. Epub 2021 Mar 17.

Authors

F Ceccarelli¹, A Botticelli², F Natalucci³, G Olivieri³, A Cirillo², C Alessandri³, P Marchetti², F Conti³

Affiliations

¹ Reumatologia, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. [email protected].
² Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
³ Reumatologia, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy.

PMID: 33728870
DOI: 10.1007/s12094-021-02584-y

No abstract available

Keywords: Antinuclear antibodies; Arthritis; Biomarkers; Immune check-point inhibitors.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Antinuclear / analysis
Antineoplastic Agents, Immunological / adverse effects*
Chemoradiotherapy / methods
Disease Progression
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immunotherapy
Male
Nivolumab / adverse effects*
Rheumatologists
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Skin Neoplasms / therapy
Squamous Cell Carcinoma of Head and Neck / drug therapy*
Squamous Cell Carcinoma of Head and Neck / immunology

Substances

Antibodies, Antinuclear
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
SS-A antibodies
Nivolumab